Exin Therapeutics

Based in San Francisco, California, Exin Therapeutics develops an artificial intelligence-driven drug discovery platform focused on genetic therapies specifically targeting neural activity for neurological and neuropsychiatric disorders. The company's proprietary technology integrates high-throughput in vivo mouse studies with computational data analysis to optimize targeted treatments for complex conditions such as epilepsy, autism spectrum disorder, and Parkinson's disease. Operating with a dedicated core team of three employees, the early-stage biotechnology startup focuses on target selection, preclinical trials, and the rapid development of neurotherapeutic pipelines. The enterprise is backed by prominent startup accelerator Y Combinator as part of its Winter 2025 batch and receives strategic advisory support from researchers affiliated with Harvard University and University College London. Exin Therapeutics was founded in 2024 by a team of Oxford-educated neuroscientists including Ivan Lazarte, Gabriel Ocana Santero, and Marko Tvrdic.

High-Level Overview

Exin Therapeutics is an AI-driven drug discovery platform focused on developing neurotherapeutics that target neural circuits to treat complex brain disorders such as epilepsy, autism spectrum disorder (ASD), Parkinson’s disease, Alzheimer’s, and schizophrenia. Their approach leverages multimodal AI models trained on high-density data from in-house high-throughput mouse studies to identify and prioritize drug candidates that modulate neural activity effectively. This circuit-level strategy supplements existing genes to directly influence brain activity, independent of genetic background, addressing the challenges of traditional brain drug development. Exin serves patients with debilitating neurological and neuropsychiatric conditions by accelerating preclinical R&D and improving therapeutic efficacy prediction, demonstrating rapid growth with early proof-of-concept results, provisional patents, and a dual-hub operational model spanning San Francisco and Manila[1][2][3][4].

Origin Story

Founded by three Oxford-trained neuroscientists, including Ivan (whose brother has ASD), Exin Therapeutics emerged from a mission to improve quality of life for patients with neurological disorders. The founders bring deep expertise in neuroscience, genetics, and AI, with backgrounds spanning systems neuroscience, iPSC models, and developmental neuroscience. Since relocating to San Francisco, the company quickly established an animal lab, achieved proof-of-concept in mice, developed a multimodal AI screening model, and filed two provisional patents—all within 1.5 months and under half of their Y Combinator funding. Supported by advisors from Harvard, UCL, Meta, and other top institutions, Exin has expanded its footprint with a major investment in a neurotherapeutics lab in Manila, aiming to scale drug candidate discovery and create high-value scientific jobs[1][2][4][5].

Core Differentiators

• Circuit-Level Therapeutic Approach: Focuses on modulating neural circuits directly rather than targeting genes individually, enabling multi-target and highly localized effects.
• Multimodal AI Models: Integrates neural activity, behavior, and transcriptomics data to predict drug candidate potential and efficacy, surpassing conventional analytical methods.
• High-Throughput In-House Mouse Studies: Combines AI with experimental validation to prioritize promising candidates efficiently.
• Genetic Background Agnostic: Therapies work independently of patients’ genetic variations, broadening applicability.
• Dual-Hub Operational Model: Computational drug discovery and business development in San Francisco; wet-lab operations and manufacturing scale-up in Manila.
• Strong Academic and Industry Network: Backed by advisors from Harvard, UCL, Meta, and others, enhancing scientific rigor and industry insight[1][2][3][4].

Role in the Broader Tech Landscape

Exin Therapeutics rides the convergence of AI, neuroscience, and gene therapy, addressing the historically difficult challenge of brain drug development. The timing is critical as advances in AI enable the analysis of complex multimodal biological data, accelerating discovery cycles and reducing costs. Market forces such as rising neurological disorder prevalence and demand for precision neurotherapeutics favor Exin’s approach. By establishing a significant presence in Southeast Asia with a cutting-edge lab, Exin also influences the global biotech ecosystem by decentralizing advanced neurotherapeutics R&D and fostering regional scientific talent. Their platform exemplifies the shift toward AI-augmented drug discovery and personalized medicine in neurotechnology[1][3][4].

Quick Take & Future Outlook

Exin Therapeutics is poised for rapid growth, scaling its drug discovery capacity from tens to potentially hundreds of candidates monthly with its planned expansion in the Philippines. Future trends shaping their journey include continued AI advancements, increasing integration of multimodal biological data, and growing demand for therapies addressing complex brain disorders. Their influence may expand as they validate more candidates and potentially enter clinical development, setting new standards for circuit-level neurotherapeutics. The company’s dual-hub model and strong academic partnerships position it well to lead innovation in AI-driven neuropharma, ultimately improving treatment options for millions worldwide[4][5]. This forward momentum ties back to their founding mission of transforming neurological disease treatment through cutting-edge science and technology.